ARS Pharmaceuticals, Inc. — Director's Dealing 2022

Nov 11, 2022

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2022-11-08

Reporting Person: Flynn James E (Director, 10% Owner, Director by deputization)
Reporting Person: Deerfield Mgmt III, L.P. (Director, 10% Owner, * Director by deputization)
Reporting Person: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (Director, 10% Owner, * Director by deputization)
Reporting Person: Deerfield Private Design Fund III, L.P. (Director, 10% Owner, * Director by deputization)
Reporting Person: Deerfield Mgmt IV, L.P. (Director, 10% Owner, * Director by deputization)
Reporting Person: Deerfield Private Design Fund IV, L.P. (Director, 10% Owner, * Director by deputization)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	5538964	Indirect
Common stock	5538964	Indirect

Footnotes

F1: This Form 3 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. ("Fund III"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. (collectively with Fund III, the "Funds"). Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt, L.P. and Deerfield Management Company, L.P.

F2: In accordance with Instruction 5 (b)(iv) to Form 3, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.